-
公开(公告)号：US10208349B2
公开(公告)日：2019-02-19
申请号：US14084047
申请日：2013-11-19
申请人： UCB BIOPHARMA SPRL
发明人： Adam Samuel Platt , Stephen Edward Rapecki , Mara Fortunato , David Robert Rainey , Jon Leigh Rundle , Paul Alfred Smith , Gillian Sairfull Watt
IPC分类号： C12Q1/68 , G01N33/68 , C12Q1/6883 , C12Q1/6886
摘要： The present invention provides the use of lipocalin 2 (LCN2) as a biomarker for IL-17 mediated diseases and for monitoring the response of a patient to anti-IL-17 therapy.
-
公开(公告)号：US10829566B2
公开(公告)日：2020-11-10
申请号：US15779426
申请日：2016-12-01
申请人： UCB BIOPHARMA SPRL
摘要： The present invention relates to a method of identifying, separating and characterizing a cell or a population of cells, by capturing at the cell surface, secreted soluble substances (such as an immunoglobulin) that cell or population of cell secrete. This is achieved by combing on a heterodimerically-tethered multispecific protein complex combining a binding specificity for the secreted molecule and a binding specificity for a surface antigen specific for that cell or population of cells. This method may be used in research and experimental purposes, such as patients' stratification in preparation of clinical trials or personalized therapies by identifying cell populations relevant to a pathology and/or prognosis.
-
公开(公告)号：US10730952B2
公开(公告)日：2020-08-04
申请号：US15326499
申请日：2015-07-16
申请人： UCB BIOPHARMA SPRL
摘要： The present disclosure relates to a multispecific molecule comprising a binding domain specific to the antigen CD45 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising same and use of each in treatment, for example treatment of autoimmune disease.
-
公开(公告)号：US20190144945A1
公开(公告)日：2019-05-16
申请号：US16248219
申请日：2019-01-15
申请人： UCB BIOPHARMA SPRL
发明人： Adam Samuel Platt , Stephen Edward Rapecki , Mara Fortunato , David Robert Rainey , John Leigh Rundle , Paul Alfred Smith , Gillian Fairfull Watt
IPC分类号： C12Q1/6883 , G01N33/68 , C12Q1/6886
摘要： The present invention provides the use of lipocalin 2 (LCN2) as a biomarker for IL-17 mediated diseases and for monitoring the response of a patient to anti-IL-17 therapy.
-
公开(公告)号：US20170275355A1
公开(公告)日：2017-09-28
申请号：US15476279
申请日：2017-03-31
申请人： UCB BIOPHARMA SPRL
CPC分类号： C07K16/244 , A61K47/60 , A61K2039/505 , C07K16/464 , C07K2317/20 , C07K2317/24 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.
-
公开(公告)号：US11692041B2
公开(公告)日：2023-07-04
申请号：US15743761
申请日：2016-07-15
申请人： UCB Biopharma SPRL
CPC分类号： C07K16/289 , C07K16/18 , C07K16/2803 , C07K2317/24 , C07K2317/31 , C07K2317/35 , C07K2317/55 , C07K2317/622 , C07K2317/624 , C07K2317/64 , C07K2317/76 , C07K2317/90
摘要： The present disclosure relates to constructs, such as antibody molecules comprising a binding domain specific to CD45, said binding domain comprising SEQ ID NO: 1, 2, 3 and/or SEQ ID NO: 4, 5 and 6. The disclosure also extends to pharmaceutical compositions comprising said constructs and use of the constructs/compositions in treatment.
-
公开(公告)号：US10370447B2
公开(公告)日：2019-08-06
申请号：US15326501
申请日：2015-07-16
申请人： UCB BIOPHARMA SPRL
摘要： The present disclosure relates to multispecific molecule comprising a binding domain specific to the antigen CD22 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising the same and use of both in treatment, for example the treatment of autoimmune disease.
-
公开(公告)号：US09890219B2
公开(公告)日：2018-02-13
申请号：US14706234
申请日：2015-05-07
申请人： UCB BIOPHARMA SPRL
IPC分类号： A61K39/395 , C07K16/46 , C07K16/24
CPC分类号： C07K16/468 , A61K39/3955 , C07K16/244 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/565 , C07K2317/76 , C07K2317/90 , C07K2317/92
摘要： The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
-
公开(公告)号：US10775385B2
公开(公告)日：2020-09-15
申请号：US15736614
申请日：2015-10-22
申请人： UCB Biopharma SPRL
发明人： James Philip O'Connell , John Robert Porter , Alastair Lawson , Boris Kroeplien , Stephen Edward Rapecki , Timothy John Norman , Graham John Warrellow , Tracy Lynn Arakaki , Alex Buntin Burgin , William Ross Pitt , Mark Daniel Calmiano , David Andreas Schubert , Daniel John Lightwood , Rebecca Jayne Wootton
IPC分类号： G01N33/68 , C07K14/525 , C07K14/705 , C07K16/24 , A61P37/00 , C07D401/14 , C07D471/00 , C07D213/72 , C07D235/04 , C07D239/26 , C07D471/04 , A61K47/64 , A61P35/00
摘要： A new, stable trimeric TNFα structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNFα/TNFR1 interaction. Membrane-bound TNFα is not affected in its ability to signal through TNFR2, and thus the new structure of TNFα may be used in therapies which do not significantly raise the risk of infection or malignancy.
-
公开(公告)号：US10590197B2
公开(公告)日：2020-03-17
申请号：US15743756
申请日：2016-07-15
申请人： UCB Biopharma SPRL
IPC分类号： C07K16/28 , A61K39/00 , A01K67/027
摘要： The present disclosure relates to antibody molecules comprising a binding domain specific to CD22, said binding domain comprising SEQ ID NO: 1, 2, 3, 4, 5 and 6 or 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.029 秒)
